TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE-MONTHS AND NINE-MONTHS PERIODS ENDED 30 SEP 2026

TOGETHER WITH LIMITED REVIEW REPORT

Tenth Of Ramadan For Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)

Interim Condensed Consolidated Financial Statements
For the Three-Months and Nine-Months Periods Ended 30 September 2026

Table of Contents **Page**

Limited Review Report	3
Condensed Consolidated Statement of Financial Position	4
Condensed Consolidated Statement of Profit or Loss	5
Condensed Consolidated Statement of Comprehensive Income	6
Condensed Consolidated Statement of Changes in Equity	7
Condensed Consolidated Statement of Cash Flows	8
Notes to the Condensed Consolidated Financial Statements	9-35

Shape the future with confidence

ALLIED FOR ACCOUNTING & AUDITING
P.O. Box 20, Katameya
Podium 1, Building No. P4
Cairo Festival City
New Cairo, Arab Republic of Egypt

Tel: +202 2726 0260
Fax: +202 2726 0100
cairo.office@eg.ey.com
https://www.ey.com

Translation of Auditor's report
Originally issued in Arabic

REPORT ON REVIEW OF INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

TO THE BOARD OF DIRECTORS OF TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

Introduction

We have reviewed the accompanying interim condensed consolidated financial position of **Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (Rameda) (S.A.E) ("The Company")** as of 30 Sep 2026, as well as the related interim condensed consolidated statements of profit or loss, Comprehensive income for the three months and nine months periods ended 30 Sep 2026, and the related interim consolidated changes in equity and cash flows for the nine months period then ended, and a summary of significant accounting policies and other explanatory notes. Management is responsible for the preparation and fair presentation of these interim condensed consolidated financial statements in accordance with Egyptian Accounting Standards No. (30) "Interim Financial Statements". Our responsibility is to express a conclusion on these Interim condensed consolidated financial statements based on our review.


Scope of Review

We conducted our review in accordance with Egyptian Standard on Review Engagements No. 2410, "Review of interim condensed consolidated Financial Statements Performed by the Independent Auditor of the Entity." A review of interim condensed consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Egyptian Standards on Auditing. Consequently, it does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Interim condensed consolidated financial statements does not give a true and fair view, in all material respects, of the interim condensed consolidated financial position of the entity as at 30 September 2026, and of its financial performance for the three months and nine months periods ended on 30 September 2026 and its interim condensed consolidated cash flows for the nine months then ended in accordance with Egyptian Accounting Standards No.(30) "Interim Financial Statements", and in light of the applicable Egyptian laws and regulations and the prevailing interpretations issued by the Financial Regulatory Authority (FRA).

Auditor



Ahmed Amin Hafez
(RAA 20904)
FESAA
FRA Register No. (403)
Cairo: 11 November 2026

Tenth Of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 Sep 2026

	Notes	*30 Sep 2026* *EGP*	*31 DEC 2025* *EGP*
ASSETS			
Non-current assets			
Fixed assets and assets under construction	(5)	**764,679,821**	719,992,976
Right of use assets	(6-A)	**65,424,031**	72,155,756
Intangible assets	(7)	**1,095,654,371**	1,110,797,408
Total non-current assets		**1,925,758,223**	1,902,946,140
Current assets			
Inventories	(8)	**916,843,269**	1,031,465,091
Trade and notes receivable	(9)	**2,579,406,752**	2,115,289,920
Due from related parties	(32)	**15,000**	25,500
Prepayments and other receivables	(10)	**183,870,802**	157,783,150
Cash on hand and at banks	(11)	**74,204,889**	36,178,688
Other assets	(12)	**-**	93,839,078
Total current assets		**3,754,340,712**	3,434,581,427
TOTAL ASSETS		**5,680,098,935**	5,337,527,567
EQUITY AND LIABILITIES			
Equity			
Paid up capital	(15)	**508,204,334**	500,000,000
Legal reserve		**250,000,000**	250,000,000
General reserve	(16)	**255,792,295**	255,792,295
Share based payments reserve	(18-a)	**50,885,034**	12,762,534
Other reserves		**278,952**	278,952
Retained earnings		**1,464,643,273**	1,148,943,876
Total equity of parent company		**2,529,803,888**	2,167,777,657
Non-controlling interest		**(11,406,872)**	42,122,663
Total equity		**2,518,397,016**	2,209,900,320
LIABILITIES			
Non-current liabilities			
Lease liabilities – noncurrent portion	(6-B)	**78,707,384**	75,460,824
Deferred tax liabilities	(29)	**83,596,500**	68,571,527
Total non-current liabilities		**162,303,884**	144,032,351
Current liabilities			
Provisions	(13)	**29,292,452**	14,970,947
Credit facilities	(19)	**2,244,042,402**	2,261,180,512
Lease liabilities – current portion	(6-B)	**2,979,514**	6,755,304
Trade, notes and other payables	(14)	**633,970,883**	584,112,797
Income taxes payable		**89,112,784**	116,575,336
Total current liabilities		**2,999,398,035**	2,983,594,896
TOTAL LIABILITIES		**3,161,701,919**	3,127,627,247
TOTAL EQUITY AND LIABILITIES		**5,680,098,935**	5,337,527,567

Chief financial officer — **Board Member**

Mohamed Abo Amira — **Amr Abdallah Morsy**

The accompanying notes from (1) to (36) are an integral part of these interim condensed consolidated financial statements.

Auditor's Limited Review Attached.

Tenth Of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS
For the Nine-Month and Three-Month Periods Ended 30 Sep 2026

	Notes	For the nine months ended *30 Sep 2026* *EGP*	*30 Sep 2025* *EGP*	For the three months ended *30 Sep 2026* *EGP*	*30 Sep 2025* *EGP*
Revenues	(22)	**3,270,551,608**	2,963,701,872	**1,149,750,640**	1,134,753,573
Cost of revenues	(23)	**(1,619,100,456)**	(1,574,550,561)	**(573,354,049)**	(618,297,782)
GROSS PROFIT		**1,651,451,152**	1,389,151,311	**576,396,591**	516,455,791
Selling and marketing expenses	(24)	**(661,556,260)**	(511,538,738)	**(236,964,278)**	(206,180,171)
General and administrative expenses	(25)	**(135,231,833)**	(114,662,678)	**(45,022,502)**	(44,095,902)
Other income	(26)	**1,920,143**	7,741,537	**1,952,553**	2,771,931
OPERATING PROFIT		**856,583,202**	770,691,432	**296,362,364**	268,951,649
Finance income	(27)	**2,741,702**	17,885,019	**578,069**	1,038,421
Finance expenses	(28)	**(374,216,194)**	(405,629,204)	**(122,275,738)**	(138,648,843)
Net foreign exchange gain		**6,246,147**	(5,841,947)	**6,717,026**	(983,067)
NET FINANCE COST		**(365,228,345)**	(393,586,132)	**(114,980,643)**	(138,593,489)
Impairment of trade and notes receivable – net	(9)	**14,408,854**	(3,951,311)	**4,226,855**	39,916
Provisions expenses	(13)	**(10,000,000)**	-	**-**	-
Share Based payment expenses	(18-b)	**(47,653,125)**	-	**(15,884,375)**	-
Contribution for health insurance		**(8,247,030)**	(7,590,359)	**(2,252,577)**	(2,791,653)
PROFITS FOR THE PERIOD BEFORE INCOME TAXES		**439,863,556**	365,563,630	**167,471,624**	127,606,423
Income taxes	(29)	**(104,168,194)**	(84,768,317)	**(36,073,540)**	(32,079,419)
PROFITS FOR THE PERIOD		**335,695,362**	280,795,313	**131,398,084**	95,527,004
Attributable to:					
Equity holders of the parent company		**340,404,129**	268,291,300	**132,986,254**	97,603,478
Non-controlling interests		**(4,708,767)**	12,504,013	**(1,588,170)**	(2,076,474)
PROFITS FOR THE PERIOD		**335,695,362**	280,795,313	**131,398,084**	95,527,004
Basic - Earnings per share	(30)	**0.1691**	0.1341	**0.0654**	0.0488
Diluted - Earnings per share	(30)	**0.1691**	0.1341	**0.0654**	0.0488

Chief financial officer
Mohamed Abo Amira

Board Member
Amr Abdallah Morsy

The accompanying notes from (1) to (36) are an integral part of these interim condensed consolidated financial statements.

Tenth Of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For the Nine-Month and Three-Month Periods Ended 30 Sep 2026

	For the nine months ended		*For the three months ended*	
	30 Sep 2026	*30 Sep 2025*	***30 Sep 2026***	*30 Sep 2025*
	EGP	*EGP*	***EGP***	*EGP*
PROFITS FOR THE PERIOD	**335,695,362**	280,795,313	**131,398,084**	95,527,004
Other comprehensive income				
Other comprehensive income that may be reclassified to profit or loss in subsequent periods (net of tax):	-	-	-	-
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	-	-	-	-
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods (net of tax):	-	-	-	-
Net other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods	-	-	-	-
Other comprehensive income, net of tax	-	-	-	-
Total comprehensive income, net of tax	**335,695,362**	280,795,313	**131,398,084**	95,527,004
Attributable to:				
Equity holders of the parent company	**340,404,129**	268,291,300	**132,986,254**	97,603,478
Non-controlling interests	**(4,708,767)**	12,504,013	**(1,588,170)**	(2,076,474)
Total comprehensive income, net of tax	**335,695,362**	280,795,313	**131,398,084**	95,527,004

The accompanying notes from (1) to (36) are an integral part of these interim condensed consolidated financial statements.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (Rameda) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the Period Ended 30 September 2026

	Paid up capital	Legal reserve	General Reserve	Treasury shares	Share based Payment	Other reserves	Retained earnings	Total equity of parent company	Non-controlling interest	Total
	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP
Balance as at 1 January 2025	378,233,733	189,116,867	327,509,944	(26,231,267)	13,029,251	278,952	1,162,330,106	2,044,267,586	27,376,784	2,071,644,370
Payments to capital increase (Note 15)	1,882,840	-	-	-	-	-	-	1,882,840	-	1,882,840
Retire Treasury shares	(2,367,500)	-	(23,863,767)	26,231,267	-	-	-	-	-	-
Share based Payment reserve (Note 18)	-	-	13,029,251	-	(13,029,251)	-	-	-	-	-
Dividend distributions	-	-	-	-	-	-	(189,600,000)	(189,600,000)	-	(189,600,000)
Total comprehensive income for the period	-	-	-	-	-	-	268,291,300	268,291,300	12,504,013	280,795,313
Balance at 30 September 2025	377,749,073	189,116,867	316,675,428	-	-	278,952	1,241,021,406	2,124,841,726	39,880,797	2,164,722,523
Balance as at 1 January 2026	**500,000,000**	**250,000,000**	**255,792,295**	**-**	**12,762,534**	**278,952**	**1,148,943,876**	**2,167,777,657**	**42,122,663**	**2,209,900,320**
Capital increase (Note 15)	**8,204,334**	**-**	**-**	**-**	**-**	**-**	**-**	**8,204,334**	**-**	**8,204,334**
Share based Payment reserve (Note 18)	**-**	**-**	**-**	**-**	**38,122,500**	**-**	**-**	**38,122,500**	**-**	**38,122,500**
Transfer non-controlling interest to Parent company	**-**	**-**	**-**	**-**	**-**	**-**	**48,795,268**	**48,795,268**	**(48,820,768)**	**(25,500)**
Dividend distributions	**-**	**-**	**-**	**-**	**-**	**-**	**(73,500,000)**	**(73,500,000)**	**-**	**(73,500,000)**
Total comprehensive income for the period	**-**	**-**	**-**	**-**	**-**	**-**	**340,404,129**	**340,404,129**	**(4,708,767)**	**335,695,362**
Balance at 30 Sep 2026	**508,204,334**	**250,000,000**	**255,792,295**	**-**	**50,885,034**	**278,952**	**1,464,643,273**	**2,529,803,888**	**(11,406,872)**	**2,518,397,016**

The accompanying notes from (1) to (36) are an integral part of these interim condensed consolidated financial statements.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (Rameda) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
For the Period Ended 30 Sep 2026

	Notes	***30 Sep 2026 EGP***	*30 Sep 2025 EGP*
OPERATING ACTIVITIES			
Profits for the period before income taxes		**439,863,556**	365,563,630
Adjustments to reconcile profit before tax to net cash flow:			
Net foreign exchange differences		**(83,459)**	24,158,350
Depreciation and amortization	(5,6,7)	**78,642,287**	86,418,056
Share based payment	(18-B)	**47,653,125**	-
Provision charged	(13)	**14,321,505**	-
Impairment of trade and notes receivable	(9)	**(14,408,854)**	3,951,311
Impairment of inventory	(8)	**17,500,000**	10,500,000
Finance income	(27)	-	(15,123,701)
Debit Interest		**361,149,789**	399,692,506
Unwinding interests of lease liabilities	(28)	**13,066,405**	5,936,698
(Gain) from sale of fixed assets	(5)	**(233,929)**	(133,974)
Losses from sale of other assets	(12)	**2,761,576**	-
Gain on write-off of lease contracts		**124,077**	-
		960,356,078	880,962,876
Change in inventories		**111,410,902**	(446,515,076)
Used of inventory provision		**(14,289,080)**	(12,550,403)
Change in trade and notes receivable		**(449,707,978)**	(340,359,503)
Change in prepayments and other receivables		**(26,087,652)**	289,955,463
Changes in due from related parties		**(15,000)**	-
Change in trade, notes and other payable		**23,936,692**	53,691,364
Cash flows provided from operating activities		**605,603,962**	425,184,721
Debit interests paid		**(344,759,020)**	(399,692,506)
Provisions used		-	(2,249,896)
Proceeds from Sales other Assets	(12)	**91,077,502**	-
Income taxes paid		**(116,605,773)**	(101,808,330)
NET CASH FLOWS PROVIDED FROM (USED IN) OPERATING ACTIVITIES		**235,316,671**	(78,566,011)
INVESTING ACTIVITIES			
Payments to acquire fixed assets	(5)	**(27,026,069)**	(26,644,424)
Payments to acquire assets under construction	(5)	**(63,397,888)**	(43,398,135)
Payments to acquire intangible assets	(7)	**(11,613,382)**	(585,140,086)
Matured treasury bills collection		-	237,200,000
Proceeds from sale of fixed assets	(5)	**1,114,037**	171,820
Investment in term deposits	(11)	-	191,603
NET CASH FLOWS (USED IN) INVESTING ACTIVITIES		**(100,923,302)**	(417,619,222)
FINANCING ACTIVITIES			
Proceed from capital increase	(15)	**8,204,334**	1,882,840
Credit facilities used	(19)	**2,417,237,422**	2,665,213,928
Payment of credit facilities	(19)	**(2,434,375,532)**	(2,018,665,243)
Dividends paid during the period		**(73,500,000)**	(108,912,501)
Lease payments		**(14,016,851)**	(8,716,272)
NET CASH FLOWS (USED IN) PROVIDED FROM FINANCING ACTIVITIES		**(96,450,627)**	530,802,752
Net change in cash and cash equivalent during the period		**37,942,742**	34,617,519
Net foreign exchange difference		**83,459**	(24,158,350)
Cash and cash equivalent - beginning of the period		**35,958,688**	64,276,456
CASH AND CASH EQUIVALENT - END OF THE PERIOD	(11)	**73,984,889**	74,735,625

The statement of cash flows excludes non-cash transactions amounting to EGP 25,500, resulting from the settlement of balances between related parties.

The accompanying notes from (1) to (36) are an integral part of these interim condensed consolidated financial statements.

1- BACKGROUND

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (the "Company" or the "Parent Company") was established under the provisions of Law No. 43 of 1974.

The Company was registered in the commercial registry under No.84008 on 15 January 1986.

The listing of Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) on the Egyptian stock exchange was approved in 26 November 2019 according to resolution of listing committee of Egyptian stock exchange.

The registered office is located at plot No. 5 Second Industrial Zone, 6th of October City – Giza– Egypt.

The consolidated financial statements include the financial statements of the Parent Company and its subsidiaries (collectively referred to as the "Group").

The Group is principally engaged in:

- Manufacturing, marketing, selling and storing pharmaceutical reagents for human and veterinary use.
- Manufacturing, marketing, selling and storing diagnostic reagents necessary for individuals, laboratories and hospitals.
- Importing pharmaceutical reagents and raw materials necessary for serving the Company's purposes without trading.
- Producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others.
- Producing food supplements for human use for others and by others.

The consolidated financial statements for the period ending 30 September 2026 were authorized for issuance in accordance with a resolution of the Board of Directors dated 10 November 2026.

Below is a brief background about the subsidiaries:

Rameda for Pharmaceuticals Trading Company

A subsidiary with 99.97% shareholding. Its principal activity is importing and exporting pharmaceutical reagents, producing, marketing, selling and storing pharmaceutical reagents and producing pharmaceutical reagents for human and veterinary and diagnostic use for others

Ramecare Company

A subsidiary with 98% legal ownership. Its principal activity is producing, marketing, selling and storing of pharmaceutical reagents, producing pharmaceutical reagents for human and veterinary and diagnostic use for others.

Ramepharma Company

A subsidiary with 98% legal ownership. Its principal activity is producing, marketing, selling and storing of pharmaceutical reagents, producing pharmaceutical reagents for human and veterinary and diagnostic use for others.

Glow Company

Tenth of Ramadan for pharmaceutical industries and diagnostic reagents (Rameda) has established Glow company with a 76% ownership, which will specialize in the development and production of cosmetics.

2- SIGNIFICANT ACCOUNTING POLICIES

2-1 BASIS OF PREPARATION INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The interim condensed consolidated financial statements for the nine months ended 30 Sep 2026 have been prepared in accordance with Egyptian Accounting Standard No. (30) 'Interim Financial Reporting', and in light of the applicable Egyptian laws and regulations and the prevailing interpretations issued by the Financial Regulatory Authority (FRA).

The interim condensed consolidated financial statements are prepared under the going concern assumption on a historical cost basis, and The Company is not subject to any significant seasonal or cyclical effects.

The interim condensed consolidated financial statements are prepared and presented in Egyptian pounds, which is the Group's functional currency

The interim condensed consolidated financial statements don't include all data and disclosures required in the annual financial statements and should be read in conjunction with the financial statements for the year ended 31 December 2025. In addition, results for the interim period ended 30 Sep 2026 are not necessarily indicative of the results that may be expected for the financial year ending 31 December 2026.

2-2 SIGNIFICANT ACCOUNTING POLICIES

The accounting policies used in the preparation of the interim Condensed Consolidated financial statements are consistent with those used in the preparation of the consolidated financial statements for the period ending on December 31, 2025.

3- SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES

The preparation of these interim condensed consolidated financial statements require management to make judgments and estimates that affect the reported amounts of revenues, expenses, assets and liabilities, the accompanying disclosures and the disclosure of contingent liabilities at the reporting date. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the assets or liabilities affected in future periods.

Estimates and their underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised.

The key judgments and estimates that have a significant impact on the interim condensed consolidated financial statements of the Company are discussed below:

3-1 Judgments

Revenue Recognition for sale of goods

In making their judgment, the management considered the detailed criteria for the recognition of revenue from the sale of goods as set out in "EAS 48 Revenue from contracts with customers'' including the judgement about whether significant risks and rewards have been transferred.

3- SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES (CONTINUED)

3-2 Estimates

Impairment of trade and other receivables

An estimate of the collectible amount of trade and other receivables is made when collection of the full amount is no longer probable. For individually significant amounts, this estimate is performed on an individual basis. Amounts which are not individually significant, but are past due, are assessed collectively and a provision is applied according to the length of time past due, based on historical recovery rates.

Provision for sales returns

The Company's management determines the estimates provision for the expected sales returns. This estimate is determined after considering the past experience of sales returns and sales volume and expiry dates of the products sold. The management periodically reviews the estimated provision amount to ensure that provision is adequate to cover the sales return.

Useful lives of fixed assets

The Company's management determines the estimated useful lives of its fixed assets for calculating depreciation. This estimate is determined after considering the expected usage of the asset or physical wear and tear. The management periodically reviews the estimated useful lives and the depreciation method to ensure that the method and the period of depreciation are consistent with the expected pattern of economic benefits from these assets.

Useful lives of intangible assets

The useful lives of intangible assets are assessed as either finite or indefinite. The assessment of indefinite life is reviewed annually to determine whether indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

The management periodically reviews the estimated useful lives and the amortization method to ensure that the method and the period of amortization are consistent with the expected pattern of economic benefits from these assets- Disclosure no.7.

Taxes

The Company is subject to income taxes in Egypt. Significant judgment is required to determine the total provision for current and deferred taxes. The Company establishes provision, based on reasonable estimates, for possible consequences of audits by the tax authorities in Egypt. The amount of such provision is based on various factors, such as experience of previous tax audits and different interpretations of tax regulations by the Company and the responsible tax authority. Such differences of interpretations may be on a wide variety of issues depending on the conditions prevailing in Egypt.

Deferred tax assets are recognized for unused accumulated tax losses to the extent that it is probable that taxable profits will be available against which the losses can be utilized. Significant management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

Impairment of non-financial assets

The Company assesses whether there are any indicators of impairment for all non-financial assets at each reporting date. The non-financial assets are tested for impairment when there are indicators that the carrying amounts may not be recoverable. When value in use calculations are undertaken, management estimates the expected future cash flows from the asset or cash-generating unit and chooses a suitable discount rate in order to calculate the present value of those cash flows.

4- SEGMENT INFORMATION

The Group's primary business segment is the production and selling of pharmaceutical products which contributes 92% of total revenue and balance 8% is contributed by toll manufacturing services (30 September 2025: 93% and 7% respectively). The Group's management monitors the business under two segments, "production and selling of pharmaceutical products" and "manufacturing for others" (Toll manufacturing) for the purpose of making business decisions.

Segment performance is evaluated based on revenue and measured consistently with revenue in the consolidated financial statement.

Accordingly, the Group's revenues during the period ended 30 Sep 2026 were reported under two segments in the interim condensed consolidated financial statements.

The Group produces and sells several pharmaceutical products and renders services as follows:

	Services	***Production and selling of pharmaceutical products***			
Period	***Toll***	***Domestic***			
	Manufacturing "Domestic"	***Export***	***Private sales***	***Tenders***	***Total***
	EGP	***EGP***	***EGP***	***EGP***	***EGP***
30 Sep 2026	**245,784,743**	**216,266,630**	**2,481,973,058**	**326,527,177**	**3,270,551,608**
30 Sep 2025	219,759,645	169,056,003	2,160,669,178	414,217,046	2,963,701,872

Revenue from the top Five customers presented 70% of total production and selling of pharmaceutical products revenues (30 September 2025: 81%).

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

5- FIXED ASSETS AND ASSETS UNDER CONSTRUCTION

	Freehold Land	Buildings	Machinery and equipment	Transportation and dragging equipment	Laboratory equipment	Tools	Office furniture and fixtures	Assets under construction	Total
	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP
Cost									
1 January 2026	**18,637,425**	**300,425,231**	**576,198,512**	**18,779,803**	**56,505,776**	**20,737,158**	**54,581,769**	**94,147,562**	**1,140,013,236**
Additions	**-**	**11,846,356**	**7,927,210**	**2,401,220**	**1,041,961**	**-**	**3,809,322**	**63,397,888**	**90,423,957**
Transferred from assets under construction	**-**	**66,769,680**	**4,173,422**	**-**	**8,860,160**	**-**	**3,732,983**	**(83,536,245)**	**-**
Disposals	**-**	**-**	**(5,286,023)**	**-**	**-**	**(30,920)**	**(122,477)**	**-**	**(5,439,420)**
30 SEP 2026	**18,637,425**	**379,041,267**	**583,013,121**	**21,181,023**	**66,407,897**	**20,706,238**	**62,001,597**	**74,009,205**	**1,224,997,773**
Accumulated depreciation									
As of 1 January 2026,	**-**	**(103,441,678)**	**(242,628,635)**	**(14,502,855)**	**(21,059,039)**	**(6,451,021)**	**(31,937,032)**	**-**	**(420,020,260)**
Depreciation for the period	**-**	**(10,114,957)**	**(23,300,234)**	**(922,730)**	**(4,211,640)**	**(1,444,220)**	**(4,863,223)**	**-**	**(44,857,004)**
Disposals	**-**	**-**	**4,482,122**	**-**	**-**	**22,338**	**54,852**	**-**	**4,559,312**
30 SEP 2026	**-**	**(113,556,635)**	**(261,446,747)**	**(15,425,585)**	**(25,270,679)**	**(7,872,903)**	**(36,745,403)**	**-**	**(460,317,952)**
Net book value as of 30 Sep 2026	**18,637,425**	**265,484,632**	**321,566,374**	**5,755,438**	**41,137,218**	**12,833,335**	**25,256,194**	**74,009,205**	**764,679,821**

- The cost of fixed assets as of 30 Sep 2026 includes EGP 113,270,881which represents fully depreciated assets that are still in use.
- The cost of asset under construction as of 30 Sep 2026 includes impairment by EGP 686,437, (EGP 686,437 as at 31 December 2025).

Depreciation for the period was allocated to the statement of profit or loss as follows:

	30 SEP 2026
	EGP
Cost of revenue	**38,845,334**
Selling and marketing expenses	**2,895,306**
General and administrative expenses	**3,116,364**
	44,857,004

calculated as follows Gains from sale of fixed assets was:

	30 SEP 2026
	EGP
Cost of disposed assets	**5,439,420**
Accumulated depreciation of disposed assets	**(4,559,312)**
Netbook value of disposed assets	**880,108**
Proceeds from sale of fixed assets	**1,114,037**
(Gains) from sale of fixed assets	**(233,929)**

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

5- FIXED ASSETS AND ASSETS UNDER CONSTRUCTION (CONTINUED)

	Freehold Land	Buildings	Machinery and equipment	Transportation and dragging equipment	Laboratory equipment	Tools	Office furniture and fixtures	Assets under construction	Total
	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP
Cost									
01 January 2025	18,637,425	294,768,429	530,797,844	18,226,904	35,726,446	14,797,847	46,761,370	33,464,541	993,180,806
Additions	-	2,311,386	22,304,280	552,899	17,958,309	5,977,036	4,556,357	102,236,034	155,896,301
Transferred from assets under construction	-	3,345,416	31,191,655	-	2,998,503	-	4,017,439	(41,553,013)	-
Disposals	-	-	(8,095,267)	-	(177,482)	(37,725)	(753,397)	-	(9,063,871)
31 December 2025	18,637,425	300,425,231	576,198,512	18,779,803	56,505,776	20,737,158	54,581,769	94,147,562	1,140,013,236
Accumulated depreciation									
As of 1 January 2025,	-	(93,620,312)	(223,372,292)	(13,311,924)	(17,434,122)	(4,740,068)	(27,543,933)	-	(380,022,651)
Depreciation for the year	-	(9,821,366)	(27,351,129)	(1,190,931)	(3,802,399)	(1,744,499)	(5,102,289)	-	(49,012,613)
Disposals	-	-	8,094,786		177,482	33,546	709,190	-	9,015,004
31 December 2025	-	(103,441,678)	(242,628,635)	(14,502,855)	(21,059,039)	(6,451,021)	(31,937,032)	-	(420,020,260)
Net book value as of 31 December 2025	18,637,425	196,983,553	333,569,877	4,276,948	35,446,737	14,286,137	22,644,737	94,147,562	719,992,976

- The cost of fixed assets as of 31 December 2025 includes EGP 114,224,464 which represents fully depreciated assets that are still in use.
- The cost of asset under construction as of 31 December 2025 includes impairment by EGP 686,437. (EGP 686,437 as at 31 December 2024).

Depreciation for the year was allocated to the statement of profit or loss as follows:

	31 December 2025
	EGP
Cost of revenue	44,810,169
Selling and marketing expenses	1,363,532
General and administrative expenses	2,838,912
	49,012,613

Gains from sale of fixed assets were calculated as follows:

	31 December 2025
	EGP
Cost of disposed assets	9,063,871
Accumulated depreciation of disposed assets	(9,015,004)
Netbook value of disposed assets	48,867
Proceeds from sale of fixed assets	197,502
(Gains) from sale of fixed assets	(148,635)

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

6- LEASES

Right of use assets are scientific rental offices, operating leases, and warehouses

A) Right of use assets

	30 Sep 2026	*31 DEC 2025*
	EGP	EGP
Cost at beginning of the period	**100,657,604**	28,026,090
Additions	**4,691,727**	72,631,514
Disposal cost of Right of use assets	**(14,296,983)**	-
Total cost at the end of the period	**91,052,348**	100,657,604
Accumulated amortization at beginning of the period	**(28,501,848)**	(19,668,642)
Disposal accumulated amortization	**9,902,395**	-
Amortization for period	**(7,028,864)**	(8,833,206)
Accumulated amortization at the end of the period	**(25,628,317)**	(28,501,848)
Netbook value at the end of the period	**65,424,031**	72,155,756

B) Lease liability

	30 Sep 2026	*31 DEC 2025*
	EGP	*EGP*
As at the beginning of the period	**82,216,128**	11,674,259
Addition	**4,691,727**	72,631,514
Disposals	**(4,270,511)**	-
Unwinding interests recognized during the period	**13,066,405**	11,165,109
Lease payments during the period	**(14,016,851)**	(13,254,754)
As at the end of the period	**81,686,898**	82,216,128
Deduct: Current portion	**2,979,514**	6,755,304
Non-current portion	**78,707,384**	75,460,824
	81,686,898	82,216,128

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

7- INTANGIBLE ASSETS

	Trademarks (acquired from third parties) *	**Registration Rights (Internally developed) ****	***IT System***	***Products Under Implementation***	***Total***
		EGP	***EGP***	***EGP***	***EGP***
Cost					
At 1 January 2025	663,693,098	8,843,008	-	9,662,736	682,198,842
Additions – internally developed	-	2,939,875	-	1,139,057	4,078,932
Acquisition	575,270,000	-	15,601,228	-	590,871,228
At 31 December 2025	1,238,963,098	11,782,883	15,601,228	10,801,793	1,277,149,002
Additions	-	-	9,485,119	2,110,243	11,595,362
Acquisition	-	-	-	18,020	18,020
At 30 SEP 2026	1,238,963,098	11,782,883	25,086,347	12,930,056	1,288,762,384
Amortization and impairment					
At 1 January 2025	(126,477,949)	(2,935,880)	-	-	(129,413,829)
Amortization	(33,957,110)	(423,885)	-	-	(34,380,995)
Impairment	-	(2,556,770)	-	-	(2,556,770)
At 31 December 2025	(160,435,059)	(5,916,535)	-	-	(166,351,594)
Amortization	(26,474,240)	(282,179)	-	-	(26,756,419)
Impairment		-	-	-	-
At 30 SEP 2026	(186,909,299)	(6,198,714)	-	-	(193,108,013)
Netbook value					
At 1 January 2025	537,215,149	5,907,128	-	9,662,736	552,785,013
At 31 December 2025	1,078,528,039	5,866,348	15,601,228	10,801,793	1,110,797,408
At 30 SEP 2026	**1,052,053,799**	**5,584,169**	**25,086,347**	**12,930,056**	**1,095,654,371**

* The balance of Trademarks (acquired from third parties) represents registration rights and trademarks relating to certain pharmaceutical products that were purchased from external parties and are legally registered. These assets are initially recognized at cost and subsequently measured using the historical cost model. These trademarks have finite useful lives and are amortized using the straight-line method over their estimated useful lives.

** The balance of intangible assets also includes registration rights for other pharmaceutical products registered by the Company with Egyptian Drug Authority (EDA). These registration rights are amortized using the straight-line method over their estimated useful lives.

- During the previous financial year ended 31 December 2025, management, as part of its periodic review of accounting estimates, reassessed the estimated useful life of certain pharmaceutical product trademarks recognized within intangible assets in accordance with Egyptian Accounting Standard (EAS) No. 23 – Intangible Assets. As a result of this review, the estimated useful life of certain trademarks was revised from the previously estimated useful life of 20 years to a revised useful life ranging from 35 to 40 years.
- This reassessment was performed in accordance with the requirements of EAS No. 23, which requires that the useful life of an intangible asset reflect the period over which future economic benefits are expected to be derived from the asset. The assessment took into consideration historical experience with similar products containing the same active ingredient, market demand, the product life-cycle stage, and industry practices relating to comparable pharmaceutical products with the same active ingredient.
- Based on an updated analysis that considered the product's expected economic life, continued medical significance, historical and projected sales performance, and the useful lives applied to comparable pharmaceutical trademarks in the market, management concluded that the previously applied useful life no longer appropriately reflected the pattern in which the future economic benefits associated with the trademarks are expected to be consumed.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

7- INTANGIBLE ASSETS (CONTINUED)

- This revision has been accounted for as a change in accounting estimate in accordance with Egyptian Accounting Standard (EAS) No. 5 – Accounting Policies, Changes in Accounting Estimates and Errors, and has been applied prospectively from the date of reassessment.

Quantitative Impact of the Change

- As a result of revising the estimated useful life to 35-40 years, the amortization expense recognized during the current period decreased by EGP 17,463,934. Comparative figures for the nine-month period ended 30 Sep 2025 have not been restated or adjusted.
- Management will continue to review the estimated useful life of the trademarks at each reporting date and will revise the estimate whenever events or changes in circumstances indicate that the expected useful life has changed, in accordance with the requirements of EAS No. 23 – Intangible Assets.

8- INVENTORIES

	30 Sep 2026	*31 DEC 2025*
	EGP	*EGP*
Raw materials	**487,657,797**	462,043,750
Packing and packaging materials	**143,716,914**	154,966,880
Spare parts	**65,810,141**	62,253,466
Finished goods	**165,060,552**	291,842,518
Work in progress	**32,100,687**	20,667,139
Goods in transit	**34,159,275**	32,785,728
Inventory with others	**1,290,736**	16,647,523
	929,796,102	1,041,207,004
Write down in inventories	**(12,952,833)**	(9,741,913)
	916,843,269	1,031,465,091

The movement in the write down in value of inventories as follows:

	30 Sep 2026	*31 DEC 2025*
	EGP	*EGP*
Beginning balance of the period	**(9,741,913)**	(16,269,147)
Charge during the period *	**(17,500,000)**	(18,495,242)
Used during the period	**14,289,080**	25,022,476
Ending balance of the period	**(12,952,833)**	(9,741,913)

*The write down in value of inventories during the period was included in the cost of sales.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

9- TRADE AND NOTES RECEIVABLES

	30 Sep 2026	*31 DEC 2025*
	EGP	*EGP*
Trade receivable	**1,148,194,820**	1,104,263,563
Trade receivable – toll manufacturing	**62,909,171**	53,596,958
Notes receivable	**1,484,842,417**	1,088,377,909
	2,695,946,408	2,246,238,430
Impairment in value of trade and notes receivables	**(116,539,656)**	(130,948,510)
	2,579,406,752	2,115,289,920

- Notes receivable amounting to EGP**839** M are mortgage as a guarantee for the credit facilities (Note **19**).

The movement of the impairment in value of trade and notes receivable are as follows:

	30 Sep 2026	*31 DEC 2025*
	EGP	*EGP*
Beginning balance of the period	**(130,948,510)**	(26,149,830)
Charged during the period	**14,408,854**	(104,798,680)
Ending balance of the period	**(116,539,656)**	(130,948,510)

The aging analysis of gross trade and notes receivable before impairment are as follows:

			Past due but not impaired				***Impaired***
	Total	***Neither past due nor impaired***	***Less than 180 days***	***From 181 to 270 days***	***From 271 to 365 days***	***More than 365 days***	
	EGP	**EGP**	**EGP**	**EGP**	**EGP**	**EGP**	**EGP**
30 Sep 2026	**2,695,946,408**	**2,496,142,171**	**82,660,181**	**-**	**-**	**604,400**	**116,539,656**
31 December 2025	2,246,238,430	1,994,567,129	33,742,609	4,227,335	1,405,378	81,347,469	130,948,510

The balances of trade receivables and notes receivable include an amount of EGP 99,378,332 related to a single customer, in addition to related parties of the same customer. The company has been negotiating with the customer to settle the outstanding debt, given that the customer has been facing delays in payment and showing negative indicators regarding its financial position, as well as defaults with other companies. In this context, real estate assets were acquired in previous years to settle part of the outstanding debt, and these assets have been disclosed in Note (12).

The company continues to negotiate with the customer to collect the remaining outstanding amounts.

As of 31 December 2025, the customer's balance before recognizing allowances amounted to EGP 99,378,332.

The company assessed the impairment of this balance on an individual basis, and as a result, an impairment loss of EGP 99,378,332 was recognized during the year ended 31 December 2025. This brought the total allowance recorded for this customer to the same amount, which equals the entire receivable balance, resulting in a net customer balance of zero as of 31 December 2025 in Jun 2026, an amount of EGP 10 million was settled against the outstanding liability, reducing the balance to EGP 89,378,332. Accordingly, the related provision was reduced by the same amount as the settlement.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

10- PREPAYMENTS AND OTHER RECEIVABLES

	30 Sep 2026	*31 DEC 2025*
	EGP	*EGP*
Prepaid expenses	**29,978,441**	10,491,247
Advances to suppliers	**89,643,776**	48,084,794
Tax authority	**33,968,788**	52,457,929
Letters of credit margin	**1,497,121**	29,422,762
Deposits with others	**5,682,706**	2,120,940
Employees' imprests and advances	**3,104,939**	3,263,586
Prepayment to customs-authority	**2,532,853**	1,943,711
Other receivables	**17,462,178**	9,998,181
	183,870,802	157,783,150

11- CASH ON HAND AND AT BANKS

	30 Sep 2026	*31 DEC 2025*
	EGP	*EGP*
a) Egyptian Pounds		
Cash on hand	**496,014**	18,296
Current accounts	**61,074,584**	27,590,766
Checks under collection	**6,000,000**	5,540,065
Term deposits	**220,000**	220,000
	67,790,598	33,369,127
b) Foreign currencies		
Cash on hand	**1,265,010**	584,797
Current accounts	**5,149,281**	2,224,764
	6,414,291	2,809,561
	74,204,889	36,178,688

Cash on hand and at banks balances are denominated in the following currencies:

	30 Sep 2026	*31 December 2025*
	EGP	EGP
Egyptian pound (EGP)	**67,790,598**	33,369,127
US dollar (USD)	**6,331,592**	2,792,211
Euro (EUR)	**82,699**	17,350
	74,204,889	36,178,688

For the purpose of cash flow statements cash and cash equivalents consist of following.

	30 Sep 2026	*30 SEP 2025*
	EGP	*EGP*
Cash in hand	**1,761,024**	1,598,305
Checks under collection	**6,000,000**	22,755,594
Current accounts	**66,223,865**	50,381,726
	73,984,889	74,735,625

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

12- OTHER ASSETS

	30 SEP 2026	*31 December 2025*
	EGP	*EGP*
Beg of the year	**93,839,078**	93,839,078
Proceeds from the sale of real estate units	**(91,077,502)**	-
Loss of Disposal of Assets	**(2,761,576)**	-
	-	93,839,078

Other assets represent the acquisition cost of real estate units (residential units) that were assigned to Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) under a preliminary sale agreement dated 28 August 2024. The units were transferred by one of the Company's customers in settlement of an outstanding receivable balance. The Company determined the acquisition value based on the market prices of comparable real estate units in the Egyptian real estate market. During the period, the Company sold all of these units.

13- PROVISIONS

	Balance as at 1 January 2026	***Charged during the period***	***Used during the period***	***Balance as at 30 Sep 2026***
	EGP	***EGP***	***EGP***	***EGP***
Provision for expected claims	**4,238,200**	**10,000,000**	**-**	**14,238,200**
Provision for sales returns*	**10,732,747**	**4,321,505**	**-**	**15,054,252**
	14,970,947	**14,321,505**	**-**	**29,292,452**

	Balance as at 1 January 2025	*Charged during the year*	*Used during the year*	*Balance as at 31 December*
	EGP	*EGP*	*EGP*	*EGP*
Provision for expected claims	6,308,097	-	(2,069,897)	4,238,200
Provision for sales returns*	10,912,747	-	(180,000)	10,732,747
	17,220,844	-	(2,249,897)	14,970,947

*Provision for sales returns is deducted from sales disclosed (Note 22).

14- TRADE, NOTES AND OTHER PAYABLES

	30 Sep 2026	*31 December 2025*
	EGP	*EGP*
Trade payables	**262,845,237**	335,190,233
Notes payables	**106,926,197**	65,156,850
Accrued expenses	**153,377,295**	134,890,738
Tax authority (other than income tax)	**24,224,155**	19,865,164
Advances from customer	**63,014,532**	18,546,086
Dividend Payables	**81,246**	687,499
Other payables	**23,502,221**	9,776,227
	633,970,883	584,112,797

Trade payables, notes and other payables are non-interest bearing.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

15- CAPITAL

- The Company's authorized capital amounted to one billion Egyptian pounds, while the issued and paid-up capital amounted to EGP 508,204,334 distributed over 2,032,817,336shares with a nominal value of EGP 0.25 per share.
- Pursuant to the resolution of the Extraordinary General Assembly dated 14 October 2020, the Board of Directors' meeting held on 4 January 2023 resolved to increase the Company's issued and paid-up capital from EGP 250,000,000 to EGP 252,112,680, an increase of EGP 2,112,680 distributed over 8,450,720 shares, funded from payments made by beneficiaries of the scheme, to be allocated entirely to the Company's employee incentive and reward scheme. Accordingly, the Company's capital issued after the increase became EGP 252,112,680 distributed over 1,008,450,720 shares with a nominal value of EGP 0.25 per share. The amount paid under capital increase reached EGP 252,112,680 as at 31 December 2023.
- An amount of EGP 2,112,680 was paid for the capital increase, and pursuant to the bank certificate issued by Arab Bank dated 9 January 2023, the Company's issued and paid-up capital was increased from EGP 250,000,000 to EGP 252,112,680, an increase of EGP 2,112,680 distributed over 8,450,720 shares.
- The Extraordinary General Assembly meeting held on 16 August 2023 resolved to increase the issued and paid-up capital by EGP 127,887,320 through the distribution of bonus shares at a ratio of 0.52253 bonus share for each original share, based on 978,980,720 shares after excluding treasury shares, with fractions rounded up in favor of small shareholders from smallest to largest, funded from the Company's distributable net profits (current year profits + retained earnings) for the financial year ended 31 December 2022. As a result, the Company's issued capital after the increase became EGP 380,000,000 distributed over 1,520,000,000 shares with a nominal value of EGP 0.25 per share. This was registered in the Commercial Register on 20 September 2023.
- The Extraordinary General Assembly meeting held on 16 August 2023 also resolved to reduce the issued and paid-up capital from EGP 380,000,000 to EGP 375,000,000, a reduction of EGP 5,000,000, through the cancellation of treasury shares listed among shares held by public and private offering shareholders, totaling 20,000,000 shares at a nominal value of EGP 0.25 per share.
- Pursuant to the resolution of the Extraordinary General Assembly dated 14 October 2020, the Board of Directors' meeting held on 27 May 2024 resolved to increase the Company's issued and paid-up capital from EGP 375,000,000 to EGP 378,233,733, an increase of EGP 3,233,733 distributed over 12,934,932 shares, funded from payments made by beneficiaries of the scheme, to be allocated entirely to the Company's employee incentive and reward scheme. Accordingly, the Company's issued capital after the increase became EGP 378,233,733 distributed over 1,512,934,932 shares with a nominal value of EGP 0.25 per share.
- An amount of EGP 3,233,733 was paid for the capital increase, and pursuant to the bank certificate issued by Arab Bank dated 2 June 2024, the Company's issued and paid-up capital was increased from EGP 375,000,000 to EGP 378,233,733, an increase of EGP 3,233,733 distributed over 12,934,932 shares.
- On 6 January 2025, 9,470,000 treasury shares were cancelled at a nominal value of EGP 0.25 per share, with a total value of EGP 2,367,500, resulting in a corresponding reduction in capital by the same amount.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

15- CAPITAL (CONTINUED)

- An amount of EGP 1,882,840 was paid for the capital increase, and pursuant to the bank certificate issued by Arab Bank dated 12 March 2025, the Company's issued and paid-up capital was increased from EGP 375,886,232 to EGP 377,749,073, an increase of EGP 1,882,840 distributed over 7,531,360 shares. The Extraordinary General Assembly meeting held on 13 May 2025 resolved to increase the issued and paid-up capital from EGP 375,886,232 to EGP 377,749,073, an increase of EGP 1,882,840 through the issuance of 7,531,360 shares with a nominal value of EGP 0.25 per share, allocated entirely to the incentive and reward scheme of Tenth of Ramadan for Pharmaceutical Industries and
- Diagnostic Reagents (Rameda) (S.A.E), funded in cash from payments made by scheme beneficiaries in accordance with the applicable scheme tranche.
- Pursuant to the Board of Directors' meeting held on 9 March 2025 approving the profit distribution plan for the financial year ended 31 December 2024, which included the distribution of bonus shares amounting to EGP 122,250,927, the Ordinary General Assembly meeting held on 29 April 2025 approved the distribution of bonus shares to shareholders amounting to EGP 122,250,927, funded entirely from the Company's distributable net profits for the year in accordance with the financial statements for the year ended 31 December 2024. The increase of EGP 122,250,927 is distributed over 489,003,708 original shares at a ratio of 0.3236 bonus share per share, with a nominal value of EGP 0.25 per share. The capital increase through bonus shares was registered in the Commercial Register on 2 November 2025.
- The Extraordinary General Assembly meeting held on 19 May 2026 approved an increase in the issued and paid-up share capital, within the limits of the authorized capital, by EGP 8,204,334, increasing the share capital from EGP 500,000,000 to EGP 508,204,334. The increase was effected through the issuance of new shares allocated entirely to the Company's Employee Stock Ownership and Incentive Scheme (ESOP) and financed in cash from the payments made by the beneficiaries of the second tranche of the scheme, in accordance with the resolution of the Extraordinary General Assembly held on 14 October 2020.

  The increase in the issued and paid-up share capital was registered with the Commercial Register on 16 June 2026, resulting in the issued and paid-up share capital becoming EGP 508,204,334, divided into 2,032,817,336 shares, with a nominal value of EGP 0.25 (twenty-five piasters) per share.

The following illustrate the structure for shareholders as at 30 Sep 2026:

	%	***No. of shares***	***Amount EGP***
Main shareholder's shares	**52.02%**	**1,057,379,965**	**264,344,991**
Other listed free shares in Stock Exchange Market	**47.98%**	**975,437,371**	**243,859,343**
	100%	**2,032,817,336**	**508,204,334**

The following illustrate the structure for shareholders as at 31 DEC 2025:

	%	No. of shares	Amount EGP
Main shareholder's shares	40.67%	813,435,146	203,350,000
Other listed free shares in Stock Exchange Market	59.33%	1,186,564,854	296,650,000
	100%	2,000,000,000	500,000,000

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

16- GENERAL RESERVE

The balance of the general reserve represents the net book value of the capital increase shares issued during 2019, amounting to EGP 486,965,000 for the issuance of 125,000,000 shares, after deducting issuance costs of EGP 64,285,000.

Pursuant to Article (94) of the Executive Regulations of the Shareholding Companies Law promulgated by Law No. 159 of 1981, an amount of EGP 89,443,310 was transferred to the legal reserve to reach 50% of the issued and paid-up capital.

The capital was reduced through the cancellation of 20,000,000 shares amounting to EGP 5,000,000 at a nominal value of EGP 0.25 per share, and an amount of EGP 34,694,932 from the general reserve balance, representing the difference between the market value of the purchased shares and their nominal value.

A balance of EGP 14,473,267 was transferred from the incentive and reward provisions, representing the fair value of shares granted to a group of employees, using the share price announced on the Egyptian Stock Exchange on the grant date, amounting to EGP 2.01 per share.

Pursuant to Article (94) of the Executive Regulations of the Shareholding Companies Law promulgated by Law No. 159 of 1981, an amount of EGP 64,116,867 was transferred to the legal reserve to reach 50% of the issued and paid-up capital.

A balance of EGP 13,927,085 was transferred from the incentive and reward provisions, representing the fair value of shares granted to a group of employees, using the share price announced on the Egyptian Stock Exchange on the grant date, amounting to EGP 1.31 per share.

The capital was reduced through the cancellation of 9,470,000 shares amounting to EGP 2,367,500 at a nominal value of EGP 0.25 per share, and an amount of EGP 23,863,767 from the general reserve balance, representing the difference between the market value of the purchased shares and their nominal value.

On 12 May 2024, the Company activated its incentive and reward program, through which a number of employees, managers, and executive board members were granted stock options for a total of 7,531,359 shares at a nominal value of EGP 0.25 per share, subject to continued service for the required period until the exercise date, in accordance with the approval of the Financial Regulatory Authority issued on 11 June 2025.

The transferred balance represents the fair value of shares granted to a group of employees amounting to EGP 13,029,251, using the share price announced on the Egyptian Stock Exchange on the grant date, amounting to EGP 1.98 per share.

Pursuant to Article (94) of the Executive Regulations of the Shareholding Companies Law promulgated by Law No. 159 of 1981, an amount of EGP 60,883,133 was transferred to the legal reserve to reach 50% of the issued and paid-up capital.

	30 Sep 2026	*31 December 2025*
	EGP	*EGP*
Beginning Balance	***255,792,295***	*327,509,944*
Transfer to legal Reserve	-	*((60,883,133*
Disposing treasury shares	-	(23,863,767)
Transfer from share based payment	-	13,029,251
	255,792,295	255,792,295

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

17- TREASURY SHARES

The Board of Directors' meetings held on February 23, 2022, May 31, 2022, and September 4,2022, decided to repurchase treasury shares not exceeding 10% of the Company's total issued share capital through the open market.

Pursuant to the Board of Directors' resolution issued on February 23, 2022, and on May 31,2022, and on September 4, 2022, the company purchased 29,470,000 shares from the stock exchange and retained them in the treasury for a total consideration of EGP 65,926,198. The consideration paid was recognized as a revaluation in the statement of shareholders' equity.

During 2022, the company purchased 20 million shares for EGP 39,694,932. According to Article 48 of Law No. 159 of 1981, the company must dispose of treasury shares to third parties within one year of acquiring them, otherwise it will be obligated to reduce its capital by the nominal value of those shares, following the established procedures. The company has currently reduced its capital by the nominal value, totaling EGP 5,000,000.

The Board of Directors meeting held on May 13, 2024, decided to approve the capital reduction procedures by disposing of the company's treasury shares, which number 9,470,000 shares, for an amount of EGP 2,367,500.

The Extraordinary General Assembly meeting held on Dec 10, 2024, approved a capital reduction by canceling the company's treasury shares, amounting to 9,470,000 shares, for an amount of EGP 2,367,500, after completing all necessary procedures for capital reduction through the cancellation of the company's treasury shares. The decision was made by the General Authority for Investment and Free Zones on January 8, 2025.

		30 September 2026		*31 December 2025*	
		Shares	***Amount EGP***	*Shares*	*Amount EGP*
Beginning Balance		-	-	9,470,000	26,231,267
Disposed during the period	Reduce capital	-	-	(9,470,000)	(2,367,500)
	Transfer to general reserve	-			(23,863,767)
		-	-	-	-

18- SHARE BASED PAYMENT RESERVE

The company has approved the reward and incentive program for employees, managers and executive board members under the program the company grant the beneficiaries Ordinary share options at the nominal value in accordance with the approval of the Extraordinary General Assembly on October 14, 2020, and this program allows employees, managers and executive board members who benefit from the incentive and reward system to own part of the company’s shares in accordance to listing and Trading Rules of Egyptian Stock Exchange under the provisions of Law 159 for year 1981 and its executive regulations and under the provision of law 95 for year 1992 and its executive regulations.

On 12 May 2024 the company activated the reward and incentive program. Giving number of employees, managers and executive board members share options for a total of 7,531,359 shares at the nominal value (0.25 EGP per share) on condition of staying in service for the required period till the exercise date which agreed with Financial regulatory authority approval on 11 June 2025.

The fair value of the granted shares for numbers of employees were 13,029,251 Egyptian Pound using the price of the share announced in the Egyptian Stock Exchange on the grant date (1.98 EGP for share) before the deduction of the nominal value of shares that would be paid by the beneficiaries in cash.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

18- SHARE BASED PAYMENT RESERVE (CONTINUED)

During the year 2025, the Company established an incentive and reward provision in accordance with the scheme tranche determined by the Incentive and Reward Committee and to be approved by the Board of Directors. This provision relates to certain employees, managers, and executive board members, and includes a promise to sell a total of 9,817,334 shares at par value (EGP 0.25 per share), conditional upon completing the required service period up to the exercise date and achieving the required performance evaluations.

A maximum number of shares was determined for each employee in accordance with the share sale agreements, with the right to exercise the purchase being limited to a maximum period of one month from the exercise date. The fair value of the total shares granted to certain employees amounted to EGP 12,762,534, based on the share price on the Egyptian Stock Exchange at the grant date (EGP 1.55), before deducting the nominal value of the share to be paid in cash by the beneficiaries under the scheme.

On 30 March 2026, the Board of Directors unanimously approved submitting a proposal to the Extraordinary General Assembly to increase the issued share capital of the company, within the limits of the authorized capital, from EGP 500,000,000 to EGP 508,204,334, representing an increase of EGP 8,204,334, through the issuance of 32,817,336 additional shares.

This increase will be effected through the issuance of new shares fully allocated to the Employees' Reward and Incentive Scheme of Tenth of Ramadan Pharmaceutical Industries and Diagnostic Reagents Company (Rameda S.A.E.), to be funded in cash by the beneficiaries of the scheme in accordance with the scheme's tranches.

On 19 May 2026, the Extraordinary General Assembly approved the increase in the Company's issued share capital, within the limits of the authorized capital, from EGP 500,000,000 to EGP 508,204,334, representing an increase of EGP 8,204,334, through the issuance of 32,817,336 ordinary shares with a nominal value of EGP 0.25 per share. The newly issued shares were allocated in full to the Company's Employee Stock Ownership and Incentive Plan and are to be funded in cash by the beneficiaries in accordance with the applicable tranche of the plan. During the period, 17,250,000 ordinary shares were granted to certain employees with an aggregate fair value of EGP 38,122,500, determined using the quoted market price of EGP 2.46 per share on the grant date, before deducting the nominal value of the shares payable in cash by the beneficiaries.

Movement of equity instruments during the period as follows:

A- Financial Position

	30 Sep 2026		*31 December 2025*	
	Amount EGP	**Shares No.**	Amount EGP	Shares No.
Balance at 1 January 2026	**12,762,534**	**9,817,334**	13,029,251	7,531,359
Granted during the period / year	**38,122,500**	**17,250,000**	12,762,534	9,817,334
Exercised during the period / year	**-**	-	(13,029,251)	(7,531,359)
At the end of the period/year	**50,885,034**	**27,067,334**	12,762,534	9,817,334

B- Profit or Loss

	For the nine months ended		**For the three months ended**	
	30Sep 2026	30Sep 2025	**30Sep 2026**	30Sep 2025
Granted during the period	**(38,122,500)**	-	**(12,707,500)**	-
Tax on share-based payment reserve	**(9,530,625)**	-	**(3,176,875)**	-
	(47,653,125)	-	**(15,884,375)**	-

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

19- CREDIT FACILITIES

The movement of the credit facilities during the period is as follows:

	30 Sep 2026 ***EGP***	*31 December 2025* *EGP*
Beginning balance of the year	**2,260,551,940**	(1,505,994,906)
Used during the period	**2,412,377,840**	(3,435,247,434)
Payment during the period	**(2,434,375,532)**	2,680,690,400
Ending balance of the period	**2,238,554,248**	(2,260,551,940)

	30 Sep 2026 ***EGP***	*31 December 2025* *EGP*
Credit facilities maturing within 12 months	**2,238,554,248**	(2,260,551,940)
Bank credit balances	**5,488,154**	(628,572)
	2,244,042,402	(2,261,180,512)

- The interest rate on the Credit facilities ranges from 15% to 20.36% as of 30 Sep 2026 (31 December 2025: Range from 15% to 25.27%).

Credit Facilities	Facility amount EGP	***30 Sep 2026*** ***EGP***	*31 December 2025* *EGP*
CIB	700,000,000	478,444,879	597,934,320
FAB	200,000,000	199,944,267	115,926,825
Arab Bank	250,000,000	191,804,088	177,500,100
ABK	120,000,000	25,732,666	94,256,469
ADIB	400,000,000	321,790,627	400,165,403
Alex Bank	300,000,000	240,273,440	147,478,063
AUB	250,000,000	247,801,153	206,386,406
ENBD	100,000,000	-	6,498,431
AWB	200,000,000	180,083,235	158,892,950
Banque Misr	300,000,000	255,862,808	204,003,066
NBK	300,000,000	96,817,085	151,509,907
Total credit facilities		**2,238,554,248**	2,260,551,940

Some of the above facilities are guaranteed by notes receivable (Note 9).

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

20- CAPITAL COMMITMENTS

On Sep 30, 2026, the Company's contractual obligations for assets under construction, machinery and equipment of production activity, which were not included in the financial statements, amounted to EGP 67,352,881compared to (EGP 58,753,983 on December 31, 2025).

On 5 December 2024, the Company signed a contract with SAP for the implementation of the SAP accounting system, with a total contract value of USD 1,517,885 payable in equal installments from March 2025 through March 2032, in addition to USD 280,000 for system implementation and operation services. The Company is currently in the preparation phase, and the system implementation is expected to commence in Jan 2027.

21- CONTINGENT LIABILITIES

	30 Sep 2026 ***EGP***	*31 December 2025* *EGP*
Undraw downs Letter of Credits *	9,833,633	6,015,569
Non-Accrued Leases **	4,377,335	13,659,643
Refundable lease insurance **	5,482,706	13,152,000
	19,693,674	32,827,212

*The Company has opened letters of credit in favor of suppliers for the importation of raw materials and production supplies. As of the reporting date, no amounts have been drawn under these letters of credit**.**

**The Company has issued cheques upon signing one of its lease agreements, representing prepaid amounts in respect of future lease periods and/or refundable security deposits recoverable upon termination of the contractual relationship.

22- REVENUES

	Nine Months ended		**Three months ended**	
	30-Sep-26 ***EGP***	*30-Sep-25* *EGP*	***30-Sep-26*** ***EGP***	*30-SEP-25* *EGP*
Sale of goods (net)	**3,024,766,865**	2,743,942,227	**1,057,912,835**	1,063,299,153
Toll manufacturing services revenue	**245,784,743**	219,759,645	**91,837,805**	71,454,420
	3,270,551,608	2,963,701,872	**1,149,750,640**	1,134,753,573

23- COST OF REVENUES

	Nine Months ended			
	30-Sep-26 ***EGP***	*30-Sep-25* *EGP*	***30-Sep-26*** ***EGP***	*30-SEP-25* *EGP*
Salaries and incentives	**204,059,986**	179,349,318	**67,448,587**	58,390,890
Social insurance and other benefit	**52,706,714**	51,356,798	**18,757,061**	19,321,689
Raw materials	**1,012,502,214**	992,990,868	**352,962,683**	421,965,237
Spare parts and materials	**41,177,277**	58,552,199	**16,717,782**	12,699,360
Government fees and medical stamps	**16,907,191**	18,768,349	**6,084,206**	5,401,756
Other operating expenses	**77,780,816**	65,723,798	**31,098,660**	29,393,646
Energy expenses	**72,054,729**	61,229,931	**28,171,672**	22,593,145
Depreciation and amortization (Note 5,6 &7)	**65,601,753**	77,065,698	**22,245,503**	26,987,423
Rent	**30,825,182**	24,010,418	**11,589,827**	9,634,983
Maintenance	**45,484,594**	45,503,184	**18,278,068**	11,909,653
	1,619,100,456	1,574,550,561	**573,354,049**	618,297,782

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

24- SELLING & MARKETING EXPENSES

	Nine Months ended		Three months ended	
	30-Sep-26	*30-Sep-25*	***30-Sep-26***	*30-Sep-25*
	EGP	*EGP*	***EGP***	*EGP*
Salaries and incentives	**256,507,818**	202,598,175	**85,854,854**	77,841,571
Social insurance and other benefit	**26,809,405**	23,763,915	**8,695,258**	8,655,539
Depreciation (Note 5,6)	**9,924,170**	7,467,324	**4,514,152**	4,796,392
Rent	**12,500**	62,500	**-**	25,000
Advertising and marketing	**368,302,367**	277,646,824	**137,900,014**	114,861,669
	661,556,260	511,538,738	**236,964,278**	206,180,171

25- GENERAL & ADMINISTRATIVE EXPENSES

	Nine Months ended		Three months ended	
	30- Sep -26	*30-Sep-25*	***30- Sep -26***	*30-Sep-25*
	EGP	*EGP*	***EGP***	*EGP*
Salaries and incentives	**91,927,968**	85,023,444	**37,044,403**	32,994,817
Social insurance and other benefit	**5,755,787**	5,269,834	**2,080,737**	1,916,338
Professional fees	**10,217,888**	3,970,710	**4,031,970**	1,046,509
Maintenance	**1,611,483**	1,529,748	**655,868**	153,103
Depreciation (Note 5)	**3,116,364**	1,885,034	**725,134**	628,619
Others	**22,602,343**	16,983,908	**484,390**	7,356,516
	135,231,833	114,662,678	**45,022,502**	44,095,902

26- OTHER INCOME

	Nine Months ended		Three months ended	
	30- Sep -26	*30-Sep-25*	***30- Sep -26***	*30-Sep-25*
	EGP	*EGP*	***EGP***	*EGP*
Gain from sale of fixed assets (Note 5)	**233,929**	133,976	**24,572**	3,210
(Loss) from sale of other assets (Note 12)	**(2,761,576)**	-	**-**	-
Other income	**4,447,790**	7,607,561	**1,927,981**	2,768,721
	1,920,143	7,741,537	**1,952,553**	2,771,931

27- FINANCE INCOME

	Nine Months ended		Three months ended	
	30- Sep -26	*30-Sep-25*	***30- Sep -26***	*30-Sep-25*
	EGP	*EGP*	***EGP***	*EGP*
Interest from treasury bills	**-**	15,123,701	**-**	-
Interest from time deposits	**2,741,702**	2,761,318	**578,069**	1,038,421
	2,741,702	17,885,019	**578,069**	1,038,421

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

28- FINANCE EXPENSES

	Nine Months ended		Three months ended	
	30- Sep -26	*30-Sep-25*	***30- Sep -26***	*30-Sep-25*
	EGP	*EGP*	***EGP***	*EGP*
Debit interests	**355,055,037**	394,822,314	**115,058,789**	131,625,651
Unwinding interests of lease liabilities (Note 6)	**13,066,405**	5,936,698	**5,127,340**	5,431,321
Bank Charges	**6,094,752**	4,870,192	**2,089,609**	1,591,871
	374,216,194	405,629,204	**122,275,738**	138,648,843

29- INCOME TAXES

	Nine Months ended		Three months ended	
	30- Sep -26	*30-Sep-25*	***30- Sep -26***	*30-Sep-25*
	EGP	*EGP*	***EGP***	*EGP*
Current income tax	**(89,143,221)**	(91,534,666)	**(33,378,303)**	(27,775,100)
Deferred income tax	**(15,024,973)**	6,766,349	**(2,695,237)**	(4,304,319)
Income tax expense	**(104,168,194)**	(84,768,317)	**(36,073,540)**	(32,079,419)

DEFERRED INCOME TAXES

	Statement of financial position		***Statement of profit or loss***	
	30-Sep-26	*30-DEC-25*	***30-Sep-26***	*30-Sep-25*
	EGP	*EGP*	***EGP***	*EGP*
Fixed assets and intangible assets	**(130,566,145)**	(111,967,013)	**(18,599,132)**	(8,943,314)
Provisions	**32,639,678**	2,466,240	**30,173,438**	196,532
Impairment of trade and notes receivables	**-**	29,441,966	**(29,441,966)**	869,179
Write down in value of inventory	**-**	2,191,930	**(2,191,930)**	(461,341)
Share based payment reserve	**14,311,416**	3,589,463	**10,721,953**	(3,664,477)
Unrealized foreign exchange differences	**18,551**	5,705,887	**(5,687,336)**	13,208,647
Others	**-**	-	**-**	5,561,123
Net deferred income taxes	**(83,596,500)**	(68,571,527)	**(15,024,973)**	6,766,349

RECONCILIATION OF THE EFFECTIVE INCOME TAX RATE

	Tax Rate	***30 Sep 2026***	*Tax Rate*	*30 Sep 2025*
		EGP		*EGP*
Profits before income taxes		**439,863,556**		365,563,630
Income tax based on tax rate	**22.50%**	**98,969,300**	22.50%	82,251,817
Non-deductible expenses		**5,198,894**		2,516,500
Effective Tax Rate	**23.68%**	**104,168,194**	23.19%	84,768,317

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

30- EARNINGS PER SHARE

Basic and diluted earnings per share were calculated by dividing the profits for the year available for distribution to the Parent Company by the weighted average number of shares outstanding during the year as follows:

	Nine Months ended		**Three months ended**	
	30-Sep-26	*30-SEP-25*	***30-Sep-26***	*30-SEP-25*
	EGP	*EGP*	***EGP***	*EGP*
Net profit attributable to shareholders of the parent company	**340,404,129**	268,291,300	**132,986,254**	97,603,478
Weighted average number of outstanding shares after the effect of treasury share purchases during the period	**2,012,862,472**	2,000,000,000	**2,032,817,336**	2,000,000,000
Effect of dilutive shares:				
Share purchase rights for employees and executive directors	-	-	-	-
Weighted average number of shares after the effect of reduction during the period	**2,012,862,472**	2,000,000,000	**2,032,817,336**	2,000,000,000
Basic earnings per share	**0.1691**	0.1341	**0.0654**	0.0488
Diluted earnings per share	**0.1691**	0.1341	**0.0654**	0.0488

As detailed in Note (15) “Issued and Paid-up Capital,” the shareholders of the Company, in accordance with the resolution of the Ordinary General Assembly held on 29 April 2025, approved the distribution of bonus shares at a rate of 0.3236 bonus shares for each original share. Accordingly, the weighted average number of outstanding shares in the comparative figures has been adjusted in accordance with Egyptian Accounting Standard No. (22) “Earnings per Share.”

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

31- TAX POSITION

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

1. Corporate Tax

- The Company is committed to filing its corporate income tax returns within the statutory deadlines in accordance with the provisions of Article 83 of the applicable Income Tax Law.
- The Company's books and records have been examined by the Egyptian Tax Authority from the commencement of operations through the fiscal year 2019, and the related tax assessments have been finalized and settled.
- The Company is currently preparing for the tax examination covering the fiscal years **2020 to 2022**.

2. Salary Tax

- The payroll tax file has been examined from the commencement of operations through the fiscal year 2022, and the related tax assessments have been finalized and settled.
- The Company is currently preparing for the tax examination covering the period from 2023 to 2025.

3. Stamp Tax

- The Company's books and records have been examined for stamp duty tax purposes through the fiscal year 2013, and the related tax assessments have been finalized and settled.
- The fiscal years 2014 to 2020 have been examined, and the related tax dispute is currently under review by the Internal Appeals Committee.
- No documentary tax examination has been conducted for the fiscal years **2021 onwards**.

4. Sales Tax

- The Company's tax records were examined for the period from the commencement of operations through the fiscal year 2015, and the related tax assessments have been finalized and settled.

5. Value Added Tax (VAT)

- The Company is registered for Value Added Tax ("VAT") in accordance with the provisions of Law No. 67 of 2016.
- The Company's books and records have been examined for the fiscal years 2016 to 2022, and the related tax assessments have been finalized and settled.
- The Company is currently preparing for the tax examination covering the period from 2023 to 2025.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

31- TAX POSITION (CONTINUE)

RAMEDA FOR PHARMACEUTICAL TRADING (S.A.E)

a) Corporate Tax

- The company provides legal procedures within the legal dates according to law 91 of year 2005.
- The Company's books and records have been examined from the commencement of operations till 2021, and the tax dues were assessed and settled.
- The Company is currently preparing for the tax examination for the years 2022 to 2023.

b) Salary Tax

- The payroll tax file has been examined from the commencement of operations till 2022, and the tax dues were assessed and settled.
- The years 2023 to 2025 are currently being prepared for examination.

c) Stamp Tax

- The Company's books and records have been examined till 2013, and the tax dues were assessed and settled.
- The years 2014 to 2020 have been examined, and the tax dues were assessed and settled.
- No documentary examination has been conducted for the years from 2021 to date.

d) Sales Tax

- The Company was examined from the commencement of operations till 2015, and the tax dues were assessed and settled.

e) VAT

- The Company is registered for VAT in accordance with the provisions of Law No. 67 of 2016.
- The Company's books and records have been examined for the years 2016 to 2022, and the tax dues were assessed and settled.
- The Company is currently preparing for the tax examination for the period from 2023 to 2025.

RAMECARE COMPANY (L.L.C.)

a) Corporate Tax

- The company submits tax returns on legal dates in accordance with Law No. 91 of 2005.
- The company was notified of a tax form (19) for the years 2015/2016, and it was appealed on the legal date, and the necessary documents are being prepared for re-examination.
- The company was notified of a tax form (19) for the year 2019, and it was appealed on the legal date.
- The years from 2018 were not notified of the inspection.

b) Salary Tax

- The company has not been notified of the examination to now.

c) Stamp Tax

- The years from the beginning of the activity until the year 2020, were inspected and settled

d) VAT

- The company has not been notified of the examination to now.

e) Social Insurance

- No insurance file has been opened for the company to date.

f) Withholding Tax

- The company has not been notified of the examination to now.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

31- TAX POSITION (CONTINUE)

RAMEPHARMA COMPANY (L.L.C.)

a) Corporate Tax

- The company submits tax returns on legal dates in accordance with Law No. 91 of 2005.
- The Company's records were inspected from year 2012 till the year 2021 and the due tax has been paid.
- Did not been inspected from 2022 till now.

b) Salary Tax

- The company has not been notified of the examination to now.

c) Stamp Tax

- The company has not been notified of the examination to now.

d) VAT

- The company has not been notified of the examination to now.

e) Social Insurance

- No insurance file has been opened for the company to date.

f) Withholding Tax

- The company has not been notified of the examination to now.

Glow Company (S.A.E.)

a) Corporate Tax

- The company submits tax returns on legal dates in accordance with Law No, 91 of 2005,
- Did not inspect till now.

b) Salary Tax

- The company has not been notified of the examination till now.

c) VAT

- The company has not been notified of the examination till now.

d) Stamp Tax

- The company has not been notified of the examination till now.

e) Withholding Tax

- The company has not been notified of the examination till now.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

32- RELATED PARTY DISCLOSURES

a) Due from related parties

For the purpose of these interim condensed consolidated financial statements, parties are considered to be related to the Group, if the Group has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Group and the party are subject to common control.

	30 SEP 2026	*31 December 2025*
	EGP	*EGP*
Eman Mohamed Wahed Mohamed El-Zomor - Ramepharma Co.	**-**	12,750
Eman Wahed Mohamed – Ramecare Co.	**-**	12,750
Hatem Ahmed Salah Eldin Diab Ahmed - Glow Co.	**7,500**	-
Fahd Ahmed Salah Eldin Diab Ahmed - Glow Co.	**7,500**	-
	15000	25,500

b) **Salaries and incentives of key managers**

The key manager's compensation during period ended 30 Sep 2026 and 30 Sep 2025 is as follows:

	30 Sep 2026	*30 SEP 2025*
	EGP	*EGP*
Salaries and incentives	**60,331,692**	51,385,915
ESOP	**38,122,500**	-
	98,454,192	51,385,915

- No provisions charged for due from related parties.

33- CAPITAL MANAGEMENT

For the purpose of the Company's capital management, capital includes issued capital and all other equity reserves attributable to the equity holders of Parent Company.

The primary objective of the Company's capital management is to maximize the shareholder value.

The Company manages its capital structure and makes adjustments in light of change in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company's monitors capital using a leverage ratio. Which are total liabilities divided by net equity. The Company's policy is to keep leverage ratio between 1 to 2.

34- FAIR VALUES OF FINANCIAL INSTRUMENTS

Financial instruments comprise financial assets and financial liabilities. Financial assets of the Company include cash on hand and at banks, trade and notes receivable, due from related parties and other receivables. Financial liabilities of the Company include credit facilities, trade and notes payable, dividends payable, income taxes payable, accrued expenses and other payables.

The fair values of the financial assets and liabilities are not materially different from their carrying value unless stated otherwise.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

35- MAJOR EVENTS

The Monetary Policy Committee of the Central Bank of Egypt, in its meeting held on Thursday, 12 February 2026, decided to reduce the overnight deposit and lending rates, as well as the Central Bank's main operation rate, by 100 basis points, bringing them to 19%, 20%, and 19.5%, respectively. The Committee also decided to reduce the credit and discount rate by 100 basis points to 19.5%.

During the period ended 30 Sep 2026, certain regions in the Middle East experienced an escalation in geopolitical tensions, which had economic implications on regional markets and the Egyptian market. This resulted in an increase in the official exchange rate of foreign currencies against the Egyptian pound. Management has assessed the potential impact of these developments on the Company's operations, financial position, and results. Based on the information currently available, including the continued operation of core business activities, it is not practicable at this stage to reliably estimate the full financial impact of these unusual events on future periods. Management has also evaluated the extent to which these events may affect the Company's ability to continue as a going concern and concluded that the use of the going concern basis in preparing the financial statements remains appropriate.

36- SUBSEQUENT EVENTS

- On 25 October 2026, the Company's Board of Directors granted preliminary approval to acquire the entire share capital of Art Pharma for Pharmaceutical Industries S.A.E., subject to a minimum of 90% of its total shares for the acquisition to be completed. The acquisition is to be effected through a share swap in exchange for the issuance of new shares by way of an increase in the Company's share capital. The Board also appointed an independent financial advisor to determine the fair value of both companies' shares and the swap ratio, in preparation for taking the necessary decisions regarding the completion of the transaction.
- The Monetary Policy Committee (MPC) of the Central Bank of Egypt (CBE) decided to raise the key policy rates by 100 bps. Accordingly, the overnight deposit rate, overnight lending rate, and the rate of the main operation were raised to 20.0 percent, 21.0 percent, and 20.5 percent, respectively. The discount rate was also raised to 20.5 percent. This decision comes amid challenging external conditions and elevated uncertainty and aims to keep expectations anchored and safeguard the disinflation trajectory.